newsfilter
← Latest News
ACCESS Newswire·

Aptevo Therapeutics Reports 1Q25 Financial Results And Provides an Update on Mipletamig

9 of 10 frontline AML patients achieve remission with mipletamig + standard of care across two trialsMipletamig triplet combination continues to outperform standard doublet benchmarkNo cytokine release syndrome observed